Literature DB >> 2517210

Primary immunodeficiency diseases. Report of a WHO sponsored meeting.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2517210

Source DB:  PubMed          Journal:  Immunodefic Rev        ISSN： 0893-5300


× No keyword cloud information.
  9 in total

Review 1.  X-linked agammaglobulinemia.

Authors:  M E Conley; J Rohrer; Y Minegishi
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

2.  Females with a disorder phenotypically identical to X-linked agammaglobulinemia.

Authors:  M E Conley; S K Sweinberg
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

3.  A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation.

Authors:  W Kreuz; M Erdös; P Rossi; E Bernatowska; T Espanol; L Maródi
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

4.  Prevalence of gallstones in patients with primary immunoglobulin deficiency. Evidence for lack of association.

Authors:  A De Santis; R Paganelli; R Stefanoni; A Di Sabatino; M Angelico
Journal:  Dig Dis Sci       Date:  1990-06       Impact factor: 3.199

5.  Effect of 12,13-phorbol dibutyrate and ionomycin on defective B cells in common variable immunodeficiency.

Authors:  A Franz; A Bryant; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

6.  Major histocompatibility complex class III genes and susceptibility to immunoglobulin A deficiency and common variable immunodeficiency.

Authors:  J E Volanakis; Z B Zhu; F M Schaffer; K J Macon; J Palermos; B O Barger; R Go; R D Campbell; H W Schroeder; M D Cooper
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

7.  Abnormal in vitro thymocyte differentiation in a patient with severe combined immunodeficiency-Nezelof's syndrome.

Authors:  A P Knutsen; D Wall; K R Mueller; J D Bouhasin
Journal:  J Clin Immunol       Date:  1996-05       Impact factor: 8.317

8.  Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases.

Authors:  Melvin Berger; Paul J Pinciaro
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

9.  Estimating the risk of re-emergence after stopping polio vaccination.

Authors:  Akira Sasaki; Yoshihiro Haraguchi; Hiromu Yoshida
Journal:  Front Microbiol       Date:  2012-05-21       Impact factor: 5.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.